surmount-1 trial tirzepatide non-diabetic weight loss GLP-1 drugs produce real loss. Around 25% of it isn't fat. In the trial, roughly a quarter of all weight lost on was lean tissue. That is 5.6 kg Tirzepatide after intensive lifestyle intervention

A number of drugs prescribed to lower ICP (particularly acetazolamide and topiramate in IIH) compromise cognitive function

Common and Systemic Side Effects Dermal/Pigmentation: General skin darkening (tanning), and crucially, the darkening and potential change in shape or size of pre-existing moles (nevi)

Cai, L.X

The results held in studies of semaglutide or tirzepatide and across subgroups stratified by follow-up duration, population, GLP-1 agonist class, weight loss profile, GLP-1 dose, and duration

The degradation follows Arrhenius kinetics: every 10C increase roughly doubles the rate of peptide bond hydrolysis